youtube_live
Q2 2026 earnings • released • EPS beat +23.81% • Revenue beat +8.91%
See resultschevron_right
NVAX:NASDAQ
Novavax Inc
$7.95
arrow_upward
+2.71%(+0.21) 1D
$7.96
arrow_upward
+0.13% (+0.010)bedtimeAfter hours
Closed: Aug 7, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$7.75
High
$8.09
Low
$7.60
Mkt. cap
1.31B
Avg. vol.
3.57M
Volume
5.70M
52-wk high
$11.97
52-wk low
$6.20
EPS
-$0.58
Beta
2.46
Shares outstanding
164.44M
No. of employees
749
Open
$7.75
High
$8.09
Low
$7.60
Mkt. cap
1.31B
Avg. vol.
3.57M
Volume
5.70M
52-wk high
$11.97
52-wk low
$6.20
EPS
-$0.58
Beta
2.46
Shares outstanding
164.44M
No. of employees
749
News stories
From sources across the web
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com
AI content may include mistakes. Learn more